Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q4 2017 · 10-K
Revenue$2.04M$2.04M+20.3% vs Q4 2016 Net Income-$16.00M-$16.00MN/M vs Q4 2016 EPS Diluted-$0.51-$0.51N/M vs Q4 2016 Operating Incomederived-$16,598,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Operating Cash Flowderived-$13,826,000N/M Free Cash Flowderived-$15,927,000N/M Margins · derivedOperating margin-813.6%+393.3 pt vs Q4 2016
Net margin-784.2%+372.0 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 6, 2018 · 65 d after period end